Refractory Hodgkin Lymphoma Clinical Trials

43 clinical trials for Refractory Hodgkin Lymphoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma — RECRUITING · PHASE1
• An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors — RECRUITING · PHASE1
• A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL — RECRUITING · PHASE2
• Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma — RECRUITING · PHASE2
• Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma — RECRUITING · PHASE2
• Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma — COMPLETED · PHASE1
• ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma — NOT_YET_RECRUITING · PHASE2
• Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant — COMPLETED · PHASE1
• Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma — COMPLETED · PHASE1
• Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL — ACTIVE_NOT_RECRUITING · PHASE2
• Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant — COMPLETED · PHASE3
• Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL — ACTIVE_NOT_RECRUITING · PHASE2
• Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies — COMPLETED · PHASE1
• Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma — COMPLETED · PHASE1
• Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer — TERMINATED · PHASE1
• Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma — COMPLETED · PHASE2
• Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma — COMPLETED · PHASE1
• Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma — COMPLETED · PHASE2
• Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma — COMPLETED · PHASE2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial — TERMINATED · PHASE1
• Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma — COMPLETED · PHASE1
• RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT — OTHER
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant — COMPLETED · PHASE2
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas — COMPLETED · PHASE1
• PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma — OTHER · PHASE2
• Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma — COMPLETED · PHASE1
• Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer — WITHDRAWN · PHASE2
• Intra-Osseous Co-Transplant of UCB and hMSC — COMPLETED · PHASE1
• Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies — COMPLETED · PHASE1
• Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma — TERMINATED · PHASE1
• NK Cells in Cord Blood Transplantation — OTHER · PHASE1
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer — COMPLETED · PHASE1
• Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma — COMPLETED · PHASE1
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer — COMPLETED · PHASE2
• Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma — TERMINATED · PHASE1
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas — COMPLETED · PHASE1
• Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma — COMPLETED · PHASE2
• INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma — TERMINATED · PHASE2
• Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer — COMPLETED · PHASE3

Refine this search